New Insights into Targeted Protein Degradation

Researchers at the University of Dundee have made significant strides in understanding the intricate workings of protein degraders, a promising class of molecules with the potential to treat previously "undruggable" diseases. This breakthrough in targeted protein degradation (TPD) offers new hope for patients with cancers and neurodegenerative disorders.

Using advanced techniques like cryo-electron microscopy and mass spectrometry, the team at the Centre for Targeted Protein Degradation (CeTPD) has revealed details of how protein degraders function at the molecular level. This newfound knowledge allows for more precise targeting of disease-causing proteins, akin to hitting a molecular "bull's eye."

Protein degraders work by redirecting the cell's protein recycling machinery to destroy specific problematic proteins. The process involves tagging these proteins with ubiquitin molecules, essentially marking them for destruction. The Dundee researchers have now identified exactly where these ubiquitin tags are added on target proteins, providing crucial insights into the degradation mechanism.

The study focused on MZ1, a protein degrader developed at Dundee, demonstrating how it positions disease-causing proteins for optimal ubiquitination. This positioning is critical for efficient protein degradation and therapeutic effectiveness.

This research, published in Science Advances, is expected to accelerate the development of new TPD drugs. With over 50 protein degrader drugs currently in clinical trials, this enhanced understanding of their mechanism could lead to more effective treatments for a range of challenging diseases.